论文部分内容阅读
目的:评价头孢哌酮钠-舒巴坦钠对慢性心力衰竭患者伴肺部感染的临床疗效。方法:选取2015年1月—2016年1月期间收治的80例慢性心力衰竭伴肺部感染患者80例,采用随机分组法将其分为对照组40例和观察组40例;对照组患者给予头孢曲松钠治疗,观察组患者给予头孢哌酮钠-舒巴坦钠治疗,比较两组患者职后的总有效率、细菌清除率和临床症状复常时间。结果:观察组患者治疗后咳嗽复常时间、体温复常时间及啰音复常时间均短于对照组(P<0.05),总有效率及细菌清除率分别为92.50%和95.55%均高于对照组分别为75.00%和72.34%(P<0.05)。结论:采用头孢哌酮钠-舒巴坦钠治疗慢性心力衰竭伴肺部感染患者,疗效较为确切,有利于清除病原菌,改善临床症状。
Objective: To evaluate the clinical efficacy of cefoperazone sodium and sulbactam sodium in patients with chronic heart failure and pulmonary infection. Methods: Eighty patients with chronic heart failure and pulmonary infection admitted from January 2015 to January 2016 were selected and randomly divided into control group (40 cases) and observation group (40 cases). Patients in the control group Ceftriaxone sodium treatment, the observation group were given cefoperazone sodium - sulbactam sodium treatment, postoperative total efficiency, bacterial clearance and clinical symptoms of two groups were compared. Results: The cough recanalization time, body temperature recovery time and the time of auscultation in observation group were shorter than those in control group (P <0.05), and the total effective rate and bacterial clearance rate were 92.50% and 95.55% respectively The control group was 75.00% and 72.34% respectively (P <0.05). Conclusion: Cefoperazone sodium - sulbactam sodium in patients with chronic heart failure and pulmonary infection, the curative effect is more exact, is conducive to the removal of pathogens and improve clinical symptoms.